Eosinophilic and non-eosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort.

[1]  P. Howarth,et al.  Clinical evaluation of type 2 disease status in a real‐world population of difficult to manage asthma using historic electronic healthcare records of blood eosinophil counts , 2021, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[2]  J. Mullol,et al.  Chronic Rhinosinusitis With Nasal Polyps and Asthma. , 2020, The journal of allergy and clinical immunology. In practice.

[3]  M. Kerkhof,et al.  Eosinophilic asthma phenotypes in the UK population , 2020 .

[4]  F. Holguin,et al.  Management of Severe Asthma Beyond the Guidelines , 2020, Current Allergy and Asthma Reports.

[5]  P. Howarth,et al.  New Perspectives on Difficult Asthma; Sex and Age of Asthma-Onset Based Phenotypes. , 2020, The journal of allergy and clinical immunology. In practice.

[6]  J. Virchow,et al.  Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. , 2020, The Lancet. Respiratory medicine.

[7]  Todor A Popov,et al.  International severe asthma registry (ISAR): protocol for a global registry , 2019, BMC Medical Research Methodology.

[8]  P. Nair,et al.  Mechanisms and therapeutic strategies for non‐T2 asthma , 2019, Allergy.

[9]  D. Price,et al.  Characterization of severe asthma worldwide: data from the International Severe Asthma Registry (ISAR). , 2019, Chest.

[10]  W. Busse,et al.  Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[11]  S. Loukides,et al.  Severe Eosinophilic Asthma , 2019, Journal of clinical medicine.

[12]  I. Pavord,et al.  Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations , 2019, Clinical and Translational Allergy.

[13]  F. Albers,et al.  Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis , 2019, Respiratory Research.

[14]  D. Price,et al.  Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study. , 2019, The journal of allergy and clinical immunology. In practice.

[15]  C. Auffray,et al.  “T2-high” in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin , 2018, European Respiratory Journal.

[16]  A. Loudon,et al.  Time of Day Affects Eosinophil Biomarkers in Asthma: Implications for Diagnosis and Treatment , 2018, American journal of respiratory and critical care medicine.

[17]  C. Porsbjerg,et al.  Validation of ATS clinical practice guideline cut-points for FeNO in asthma. , 2018, Respiratory medicine.

[18]  K. Kostikas,et al.  Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD , 2018, Current drug targets.

[19]  F. E. Lee,et al.  Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease , 2018, Clinical Reviews in Allergy & Immunology.

[20]  I. Pavord,et al.  Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.

[21]  Richard Beasley,et al.  After asthma: redefining airways diseases , 2017, The Lancet.

[22]  M. Kraft,et al.  Eosinophilic and Noneosinophilic Asthma , 2018, American journal of respiratory and critical care medicine.

[23]  I. Pavord,et al.  The Lancet Asthma Commission: Towards the Abolition of Asthma? , 2018, European Medical Journal.

[24]  E. Bleecker,et al.  Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. , 2018, The Lancet. Respiratory medicine.

[25]  D. Price,et al.  Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population , 2017, Thorax.

[26]  I. Pavord,et al.  Severe eosinophilic asthma: a roadmap to consensus , 2017, European Respiratory Journal.

[27]  K. Chung,et al.  Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study , 2016, Respiratory Research.

[28]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[29]  Jérémie F. Cohen,et al.  Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. , 2015, The Lancet. Respiratory medicine.

[30]  D. Curran‐Everett,et al.  Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. , 2014, The Journal of allergy and clinical immunology.

[31]  Nicolas Roche,et al.  Identification of Clinical Phenotypes Using Cluster Analyses in COPD Patients with Multiple Comorbidities , 2014, BioMed research international.

[32]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[33]  D. Curran‐Everett,et al.  Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. , 2010, American journal of respiratory and critical care medicine.

[34]  C. Lenfant,et al.  Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .

[35]  A. Zwinderman,et al.  Sputum induction in severe asthma by a standardized protocol: predictors of excessive bronchoconstriction. , 2001 .

[36]  H. Brown.  Treatment of chronic asthma with prednisolone; significance of eosinophils in the sputum. , 1958, Lancet.